MedPath

Protective effect of Early shenfu injection on septic cardiomyopathy in elderly patients with SEPSIS in ICU: a randomized, controlled, multicenter clinical trial

Phase 1
Completed
Conditions
Sepsis cardiomyopathy
Registration Number
ChiCTR2400088766
Lead Sponsor
Zhongnan Hospital of Wuhan University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) Age: ?60 years old;<br>(2) Sepsis was diagnosed (according to sepsis 3.0 diagnostic criteria: infection caused host response disorder, resulting in life-threatening organ function damage);<br>(3) There is no sepsis cardiomyopathy (diagnostic criteria for sepsis cardiomyopathy: there is no unified diagnostic criteria at present, which is defined as excluding acute coronary syndrome and stress cardiomyopathy based on previous studies. Cardiac ultrasound showed left ventricular systolic dysfunction, and EF<50% or cTnI higher than 2 times the normal value);<br>(4) Informed consent signed by the patient or his/her agent.

Exclusion Criteria

(1) Patients with allergic history or contraindications to Shenfu injection (such as recent history of cerebral hemorrhage);<br>(2) pregnant women;<br>(3) Patients unable to complete bedside cardiac ultrasound examination for various reasons;<br>(4) Patients after cardiac surgery;<br>(5) The patient concurrently participates in another clinical study;<br>(6) Patients with serious underlying heart disease, such as dilated heart disease, valvular disease, ventricular septal defect, congenital heart disease, etc.<br>(7) Patients who can expect to die within 48 hours;<br>(8) Patients considered unsuitable for the study by the researcher for various reasons.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of sepsis cardiomyopathy;
Secondary Outcome Measures
NameTimeMethod
When sepsis cardiomyopathy occurs;7 days heart function recovery rate;14 days heart function recovery rate;28-day mortality rate;
© Copyright 2025. All Rights Reserved by MedPath